News >

Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases

Danielle Ternyila
Published: Thursday, May 23, 2019

Myung-Ju Ahn, MD

Myung-Ju Ahn, MD
Osimertinib (Tagrisso) at a once-daily dose of 80 mg demonstrated similar signs of activity, as well as a clinically meaningful benefit in patients with EGFR T790M–positive advanced non–small cell lung cancer (NSCLC) who had radiographically detected leptomeningeal metastases (LM) compared with the 160-mg dose observed in the AURA LM trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication